drugset / Trial / NCT02722512
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Phase 1
Terminated
10 enrolled
Ann & Robert H Lurie Children's Hospital of Chicago
Northwestern University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine is an feasible and safe treatment for pediatric patients with newly-diagnosed High-Grade Gliomas or recurrent, resectable High-Grade Gliomas and Ependymomas.
Timeline
- Start
- 2016-07
- Primary completion
- 2019-11-13
- Completion
- 2019-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | vitespen | Vaccine | — | Other |